Revenue: $598 million, down 0.8% on a constant currency basis. Non-GAAP EPS: $0.68, an increase of 9% versus prior year. Free Cash Flow: $141 million, up 493% versus prior year. US Spine Growth: 2% in Q1. Enabling Technology Sales: $22 million, a decrease of 31% versus prior year. International Spine Implant Growth: 1% on a constant currency basis. Combined Trauma and NSO Business: Declined 8% in Q1. GAAP Net Income: $75.5 million, with GAAP EPS of $0.54. Adjusted Gross Profit: 67.3%, compared to 69% in the prior year quarter. R&D Expenses: $33.1 million or 5.5% of sales. SG&A Expenses: $242.8 million or 40.6% of sales. Cash Equivalents and Marketable Securities: $461.3 million as of March 31, 2025. Net Cash Provided by Operating Activities: $177.3 million. Adjusted EBITDA: 29.7% versus 25.4% in the prior year quarter. 2025 Net Sales Guidance: $2.8 billion to $2.9 billion. 2025 Non-GAAP EPS Guidance: Revised to $3.00 to $3.30.

Warning! GuruFocus has detected 4 Warning Signs with GMED.

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Globus Medical Inc (NYSE:GMED) achieved a significant increase in free cash flow, reaching $141 million, which is a 493% increase compared to the previous year. The company successfully returned to a debt-free status by paying off nearly $900 million of debt inherited from the NuVasive merger. Globus Medical Inc (NYSE:GMED) launched two new products in Q1, which are expected to drive market penetration and enhance their product portfolio. The US spine business showed resilience with a 2% growth in Q1, driven by high retention rates and strong product offerings. The acquisition of Nevro Corporation is seen as a strategic move to expand into a $3 billion market space, enhancing Globus Medical Inc (NYSE:GMED)'s reach in the musculoskeletal market.

Negative Points

Globus Medical Inc (NYSE:GMED) experienced a slight decline in Q1 revenue, down 0.8% on a constant currency basis, due to softer enabling technology sales and supply chain disruptions. The company faced temporary integration-related supply chain disruptions, impacting sales and causing back orders. Enabling technology sales decreased by 31% compared to the previous year, attributed to an elongated selling cycle and market uncertainty. The international spine implant business grew only 1% in Q1, affected by the timing of distributor orders and supply chain issues. The combined trauma and NSO business declined by 8% in Q1, primarily due to integration-related supply chain disruptions.

Story Continues

Q & A Highlights

Q: Can you discuss your confidence in recovering from the Q1 challenges and what might spill into Q2? A: Daniel Scavilla, President and CEO, explained that the transition to new facilities and scaling up in-house manufacturing took longer than expected, causing back orders. However, they are seeing positive effects in the US spine business and are remedying supply chain issues. He expressed confidence that these are temporary issues and expects recovery in Q2.

Q: How do you plan to achieve synergies with the Nevro acquisition? A: Keith Pfeil, CFO and COO, stated that the focus will be on reducing operational expenses, particularly SG&A, which are currently too high for Nevro to operate profitably long-term. They aim to address these expenses to drive efficiencies.

Q: Have you seen any impact from competitors' new spine robots, and are there changes in financing options for your robots? A: Keith Pfeil noted that they haven't seen competitors slowing down their process. While the mix of sales options like rentals and third-party financing is increasing, outright sales remain the focus. Competitor robots have not delayed their deal closures.

Q: Can you provide insights into your expectations for EBITDA margins in 2025 with the Nevro acquisition? A: Keith Pfeil mentioned that while they don't guide EBITDA margins, they aim to achieve margins in the high 20s this year, considering the timing of the Nevro acquisition.

Q: How is the sales rep retention, especially with legacy NuVasive reps, and what are your cash flow expectations post-Nevro deal? A: Daniel Scavilla confirmed no unusual departures among sales reps, and the teams are performing well. Keith Pfeil added that they plan to continue generating strong cash flow, focusing on internal investment and potential tuck-in acquisitions, with share repurchases as part of their capital structure.

Q: Is Nevro fully included in your guidance, and what is your organic growth guidance? A: Keith Pfeil confirmed that Nevro is included in their business guidance, but they haven't broken out the parts and pieces. The components of their organic guide are not materially different on a standalone basis.

Q: Can you elaborate on the integration of Nevro and the potential for execution misses? A: Daniel Scavilla emphasized that Nevro was an opportunistic buy with long-term potential, separate from their robotics and spine operations. Keith Pfeil added that they are confident the worst of the Q1 issues are behind them, with production coming online and supply chain disruptions resolved.

Q: What impact do tariffs have on your margins? A: Keith Pfeil stated that they don't see any material impact from tariffs on margins, as they are predominantly vertically integrated and have taken actions like vendor cost renegotiations to offset potential impacts.

Q: How did supply disruptions affect US spine growth, and what was the impact on enabling tech sales? A: Daniel Scavilla acknowledged that supply disruptions impacted US spine growth, but they are improving. He also noted that enabling tech sales were down 31%, with some deals carrying over to Q2, but they are seeing lifts in sales.

Q: Why does the top-line guidance remain the same despite closing the Nevro deal earlier? A: Keith Pfeil explained that they are being conservative on the revenue view for Nevro, focusing on driving profitable growth and getting the spending right, despite the earlier deal closure.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments